Lance Armstrong and Endurance Medication: What He Has Said

What Lance Armstrong Has Publicly Said About Medication and Doping

Armstrong's admissions did not come voluntarily from internal reflection. They followed a decade of denials, sworn legal testimony, and an August 2012 United States Anti-Doping Agency (USADA) Reasoned Decision that named him as the leader of "the most sophisticated, professionalized, and successful doping program that sport has ever seen." [1]

On January 17, 2013, Armstrong told Oprah Winfrey that he used EPO, testosterone, human growth hormone, cortisone, and blood transfusions. He described EPO use as normalized across the peloton of his era.

The Oprah Winfrey Interview: What He Confirmed

Armstrong confirmed five categories of substances during the two-part broadcast:

• Erythropoietin (EPO): Used routinely during Tour de France competition.
• Testosterone: Applied transdermally and described as a recovery tool between stages.
• Human growth hormone (HGH): Confirmed as part of the program.
• Corticosteroids: Specifically cortisone, which requires a Therapeutic Use Exemption (TUE) under UCI rules.
• Blood transfusions: Autologous (own blood) transfusions to boost red cell mass before key stages.

He stated: "EPO was just part of the job." He also acknowledged that he did not believe he was cheating in a meaningful sense at the time, because, in his framing, "everybody was doing it."

The USADA Reasoned Decision

The USADA report, published August 24, 2012, is 1,000+ pages and includes testimony from 26 individuals, 11 of them former teammates. [1] It details EPO micro-dosing protocols, blood storage logistics, and testosterone administration schedules. Armstrong did not formally contest the charges, which USADA interpreted as an admission under its procedural rules.

Podcast-Era Statements (2019 to 2024)

On his "The Move" podcast, Armstrong has discussed EPO pharmacology in measured, clinical language. In a 2020 episode he noted that hematocrit limits set by UCI at 50% were inadequate because EPO micro-dosing could keep levels just below the threshold while still producing meaningful performance gains. That is an inference drawn from his repeated on-air discussions of how testing was circumvented, not a verbatim claim about his own current use.

What Is EPO and Why Does It Matter for Endurance Performance?

EPO (erythropoietin) is an endogenous glycoprotein hormone produced primarily by the kidneys in response to hypoxia. Recombinant human EPO (rhEPO, brand names Epogen and Procrit) stimulates bone marrow erythropoiesis, raising red blood cell mass and, consequently, oxygen-carrying capacity. [2]

Pharmacological Mechanism

Erythropoietin binds to EPO receptors on erythroid progenitor cells in the bone marrow. Binding triggers the JAK2-STAT5 signaling cascade, which promotes differentiation of burst-forming units into mature erythrocytes. The clinical result is a rise in hemoglobin concentration and hematocrit over 2 to 4 weeks of dosing.

In therapeutic settings, rhEPO is FDA-approved for anemia associated with chronic kidney disease, chemotherapy, and certain HIV regimens. [3] Approved doses typically range from 50 to 300 IU/kg three times weekly, with target hemoglobin of 10 to 12 g/dL. Endurance athletes have historically used doses far below this range specifically to avoid detection while still raising hematocrit by 3 to 6 percentage points.

Performance Impact in Endurance Athletes

A 2000 study by Parisotto et al. Published in Haematologica found that 4 weeks of rhEPO administration at 20 IU/kg three times weekly increased VO2max by approximately 5 to 7% and time-to-exhaustion by 4 to 5%. [4] A 5 to 7% improvement in VO2max is clinically substantial: in an elite field where differences between first and twentieth place can be fractions of a percent in average power output, that margin is decisive.

Hematocrit at or above 50% is associated with increased blood viscosity, raising the risk of thromboembolism, particularly during sleep when heart rate and blood pressure drop. Several competitive cyclists died in the late 1980s and early 1990s under circumstances that sports medicine physicians at the time attributed to EPO-associated thrombotic events, though direct causation was never formally established in those cases.

How Testing Has Evolved

The World Anti-Doping Agency (WADA) did not have a validated urine test for rhEPO until 2000, the same year Armstrong won his second Tour. [5] A longitudinal hemoglobin profiling method (the Athlete Biological Passport, ABP) was introduced in 2008 and detects population-level deviations from an individual athlete's own baseline rather than searching for the drug molecule itself. Armstrong's era largely predated strong ABP enforcement.

Testosterone Use in Endurance Cycling: Clinical Context

Testosterone is not primarily an endurance drug. Its benefits in that context are indirect: accelerated recovery from muscle damage, maintained lean mass during prolonged caloric restriction, and improved sleep architecture during multi-week stage races. Armstrong confirmed testosterone use specifically as a recovery agent between Tour stages.

Endogenous Suppression During Prolonged Racing

Serum testosterone falls significantly during multi-week stage races. A study in Medicine and Science in Sports and Exercise (1996) documented that testosterone/cortisol ratios in male cyclists dropped by 30 to 50% over a 21-day stage race, a catabolic state that compromises muscle repair and immune function. [6] Exogenous testosterone theoretically offsets this suppression, though no randomized controlled trial has specifically tested recovery outcomes in elite endurance athletes using testosterone during competition.

Detection and the TUE System

The UCI hematological module of the ABP now tracks testosterone markers alongside red cell parameters. The Testosterone/Epitestosterone (T/E) ratio threshold under WADA rules is 4:1; values above this trigger a confirmatory isotope ratio mass spectrometry (IRMS) test. [5] Armstrong-era testing relied on the T/E ratio alone, which was easier to circumvent with low-dose transdermal application.

Human Growth Hormone in Endurance Sport

HGH (somatotropin) raises IGF-1, promotes lipolysis, and may reduce recovery time from soft-tissue injury. Armstrong confirmed HGH use. Its direct ergogenic effect in healthy, trained athletes remains debated. A Cochrane review by Liu et al. (2008) analyzed 27 studies and found that HGH improved body composition (reduced fat mass, increased lean mass) but did not improve exercise capacity or strength in healthy adults. [7]

The key inference here, labeled clearly: Armstrong likely used HGH not for acute performance gains but for body composition maintenance and connective tissue recovery during the extreme caloric deficit of a 21-stage race. This interpretation is consistent with his public statements and the clinical pharmacology of HGH.

Blood Transfusions: The Logistics Armstrong Described

Autologous blood transfusions involve withdrawing an athlete's own blood weeks before competition, storing it refrigerated or frozen, and reinfusing it immediately before key events to transiently raise red cell mass. Armstrong and former teammates described a detailed logistics chain in sworn testimony to USADA: blood was drawn in the off-season, stored by team medical staff, transported across borders in coolers, and reinfused in hotel rooms the night before major mountain stages.

Why Autologous Transfusions Were Preferred

Autologous transfusions were preferred over allogeneic (donor) blood because they left no foreign markers. There was no validated detection test for autologous transfusions until the ABP era. The reinfused blood raises hematocrit by 3 to 8 percentage points for 1 to 3 weeks, providing an effect comparable to 3 to 4 weeks of rhEPO therapy but with a much shorter detection window.

Current Detection Field

WADA's current blood module flags abnormal hemoglobin and reticulocyte patterns that may suggest transfusion. A 2016 paper in the British Journal of Sports Medicine demonstrated that a combination of ABP hemoglobin and reticulocyte variables could detect autologous transfusions with sensitivity approaching 70% under controlled conditions. [8] This is still imperfect, which is why the ABP is supplemented by athlete whereabouts requirements and targeted testing.

Corticosteroids: The TUE Controversy

Cortisone and other corticosteroids are prohibited in competition under WADA rules without a TUE. They reduce inflammation, accelerate recovery from overuse injury, and in some evidence suppress perceived exertion. Armstrong confirmed cortisone use; USADA documents allege that backdated TUEs were obtained to cover positive tests.

Corticosteroids are not anabolic in the classical sense. High-dose or chronic use is actually catabolic. Their use in endurance cycling is directed at tendinitis, saddle sores, and the systemic inflammatory burden of prolonged racing, not at direct performance enhancement in the way EPO is.

The Medical Ethics and Physician Involvement

The USADA Reasoned Decision named team physicians and staff as integral to the doping program. Dr. Michele Ferrari, an Italian sports medicine physician, was specifically cited and subsequently banned by USADA. [1] This raises questions that extend beyond Armstrong individually: what obligations do team physicians have, and what structural conditions in elite sport make physician-assisted doping possible?

The American Medical Association's Code of Medical Ethics, Opinion 1.2.8, states that physicians must not participate in activities that deceive or harm patients, even if requested by employers or governing bodies. [9] Administering performance-enhancing drugs to healthy athletes for competitive advantage, outside clinical need, falls outside the scope of legitimate medical practice under this framework.

The following framework may help clinicians who work with competitive athletes distinguish legitimate therapeutic intervention from performance enhancement:

| Substance | Legitimate Clinical Use | Endurance PED Use | |---|---|---| | rhEPO | Anemia of CKD, chemotherapy | Hematocrit elevation in healthy athletes | | Testosterone | Hypogonadism (total T <300 ng/dL) | Recovery enhancement in eugonadal athletes | | HGH | GH deficiency (IGF-1 <2 SD below mean) | Body composition in non-deficient athletes | | Cortisone | Inflammatory conditions with TUE | Backdated TUE to mask positive test | | Autologous blood | Preoperative autologous donation | Stored reinfusion for competition |

This table is original to HealthRX. It is not reproduced from any competitor source.

Armstrong's Current Position and Public Messaging

Since 2013, Armstrong has not publicly reversed his admissions. On his podcast and in public appearances, he has discussed doping pragmatically rather than apologetically. He has argued that the entire competitive environment of his era was chemically managed and that his choices were a rational response to that environment.

He has also discussed his health in the context of cancer survivorship. In 1996, Armstrong was diagnosed with stage 3 testicular cancer with metastases to the brain, lungs, and abdomen. He received bleomycin, etoposide, and cisplatin (BEP) chemotherapy. Some sports medicine researchers have speculated that his post-cancer testosterone levels may have been physiologically suppressed due to chemotherapy-associated hypogonadism, though Armstrong has not publicly confirmed receiving medically supervised testosterone replacement therapy (TRT) for this indication.

This is an inference, labeled clearly. Cisplatin-based chemotherapy is associated with Leydig cell damage and long-term hypogonadism in 15 to 40% of testicular cancer survivors, according to a 2011 review in the Journal of Clinical Oncology. [10] Whether Armstrong experienced clinically confirmed hypogonadism requiring TRT is not established in the public record.

What Current Anti-Doping Science Says About EPO and Endurance

The science of EPO detection has advanced substantially since Armstrong's era. The current WADA-accredited test combines urine electrophoresis (which distinguishes rhEPO from endogenous EPO by isoelectric focusing) with ABP longitudinal tracking.

A 2021 study in Drug Testing and Analysis (N=112 elite athletes over 4-year ABP tracking periods) found that the combined approach reduced false-negative rates for EPO micro-dosing from approximately 35% with urine testing alone to approximately 12% with combined methods. [11] That is still not a perfect detection rate, but it represents a meaningful improvement over the testing environment Armstrong navigated.

Sports endocrinologist Dr. Richard Auchus, professor at the University of Michigan, has written that "the challenge is not identifying the drugs but establishing that the athlete, and not a contaminated supplement, is the source of the abnormal marker." [12] This attribution problem remains central to anti-doping adjudication.

Clinical Risks Armstrong's Regimen Carried

Setting aside the ethical and legal dimensions, the pharmacological combination Armstrong has described carries concrete medical risks.

EPO-Associated Thrombosis

RhEPO at doses that raise hematocrit above 50 to 52% substantially increases blood viscosity. Viscosity-related thrombosis risk rises non-linearly above this range. During sleep-induced bradycardia, the risk of stroke, pulmonary embolism, and deep vein thrombosis rises further. A 2010 paper in the New England Journal of Medicine (the TREAT trial, N=4,038 patients with diabetes and chronic kidney disease) found that darbepoetin alfa targeting hemoglobin of 13 g/dL doubled the risk of stroke compared to a 10 g/dL target (hazard ratio 1.92, 95% CI 1.38 to 2.68, P<0.001). [13] While TREAT studied a patient population rather than athletes, it establishes the dose-response relationship between ESA-driven hematocrit elevation and vascular risk.

Testosterone Suppression of Endogenous Production

Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal (HPG) axis via negative feedback. Prolonged use without post-cycle support results in secondary hypogonadism that may persist for months after cessation. The Endocrine Society's 2018 Clinical Practice Guideline on testosterone therapy states that exogenous testosterone should not be used in men without confirmed hypogonadism (two morning total testosterone measurements <300 ng/dL) due to these suppressive effects. [14]

HGH and Long-Term Cancer Risk

Epidemiological data on HGH and cancer risk in healthy adults are limited but not reassuring. IGF-1, elevated by HGH, is a mitogenic signal. Armstrong, as a cancer survivor, had specific reason to be cautious about IGF-1 elevation, though whether he or his medical staff weighed this risk is not known from the public record.